The market for direct-to-consumer genetic testing is projected to grow significantly, with estimates indicating it will expand from approximately US$ 1,715.84 million in 2022 to around US$ 7,191.68 million by 2030. This growth represents a compound annual growth rate (CAGR) of 19.6% over the period from 2022 to 2030.
Several factors are contributing to the expansion of the direct-to-consumer genetic testing market. The rising prevalence of genetic disorders, coupled with an increasing awareness of the advantages associated with genetic testing, is propelling market growth. However, challenges such as high costs and concerns regarding privacy are hindering the market's progress.
Growing Awareness of the Benefits of Genetic Testing
There is a notable increase in consumer interest driven by self-discovery and empowerment, as more individuals become aware of genetic testing services and the counseling that follows. Globally, acceptance and understanding of genetic testing are on the rise. This transition from passive consumers to proactive, informed individuals is a key factor in the growth of the genetic testing market. The accessibility of direct-to-consumer genetic testing (DTC-GT) is a significant advantage, allowing consumers to easily access their genetic data along with personalized insights and recommendations. Many sectors are witnessing a surge in demand for customized products and experiences, with consumers willing to invest in solutions that cater to their unique needs.
Genetic testing is crucial in managing the increasing incidence of various health conditions, including diabetes and certain cancers, by reducing unnecessary tests and guiding individuals toward the most effective prevention, treatment, and monitoring options. The role of genetic testing in medicine is expanding rapidly, facilitating quicker diagnoses and helping to identify individuals at risk for serious diseases. Preconception and prenatal genetic testing provide essential information to prospective parents regarding their carrier status for genetic disorders, aiding in informed reproductive choices.
As awareness of genetic variations linked to a wide array of diseases grows, it is expected to further stimulate market growth. These tests can indicate whether an individual has a genetic predisposition to specific diseases, enabling early diagnosis and timely intervention. The initial sequencing of the human genome and advancements in genome sequencing technologies have spurred rapid developments in genomics research, leading to the emergence of direct-to-consumer genetic testing as a viable service. The global market for DTC genetic testing has gained traction, as these tests offer valuable insights into health risks, personal traits, and overall wellness. Additionally, the swift transition of clinical laboratory professionals to DTC-GT is a vital factor driving market expansion. For instance, a report from MIT Technology Review noted that around 8% of the US population, or nearly 26 million individuals, underwent DNA testing in 2019, with projections suggesting this number could exceed 100 million in the near future.
Consequently, the increasing public awareness regarding genetic testing is a significant driver of the direct-to-consumer genetic testing market.
Segmental Analysis of the Direct-to-Consumer Genetic Testing Market
The direct-to-consumer genetic testing market is categorized based on test type, technology, and distribution channel. In terms of test type, the market is divided into ancestry testing, nutrigenomics testing, predictive testing, carrier testing, and others. The ancestry testing segment dominated the market in 2022, while the predictive testing segment is expected to experience the highest CAGR from 2022 to 2030.
When examining technology, the market is segmented into whole genome sequencing, single nucleotide polymorphism (SNP) chips, targeted analysis, and others. The SNP chips segment held a significant market share in 2022 and is projected to achieve a higher CAGR during the forecast period.
Regarding distribution channels, the market is divided into online and offline segments. The online segment captured the largest market share in 2022 and is anticipated to grow at the highest CAGR from 2022 to 2030.
Geographical Insights into the Direct-to-Consumer Genetic Testing Market
Geographically, the direct-to-consumer genetic testing market is analyzed across North America, Europe, Asia Pacific, the Middle East & Africa, and South and Central America. North America holds a substantial market share, driven by the rising incidence of genetic disorders, significant investment in research and development, product approvals from the US Food and Drug Administration (FDA), and technological advancements. The expanding healthcare sector and the increasing adoption of direct-to-consumer genetic testing are expected to create further growth opportunities in this region during the forecast period. Additionally, government initiatives aimed at addressing the rising concerns surrounding genetic diseases are supporting the growth of the DTC genetic testing market in North America. The US, in particular, has the largest market share in this sector, with the FDA approving 23andMe's DTC genetic test for a hereditary prostate cancer marker in 2022. The popularity of direct-to-consumer genetic testing continues to rise in the US, as highlighted by the US National Institutes of Health (NIH), which notes that these tests are marketed directly to consumers through various media channels.
Furthermore, the Asia Pacific region is anticipated to experience the fastest growth rate during the forecast period. The expansion of the DTC genetic testing market in this region is attributed to the increasing demand for advanced treatment options, heightened awareness of early genetic disorder screening, and a growing emphasis on research and development. Additionally, advancements in genomics research, a large patient population, and improvements in healthcare infrastructure are expected to drive the growth of the direct-to-consumer genetic testing market in Asia Pacific.
Europe ranks second in terms of market share for direct-to-consumer genetic testing, with significant growth anticipated in the coming years due to rising awareness of genetic testing and the increasing prevalence of genetic disorders and cancers. Germany leads the European market, while the UK is projected to experience the fastest growth during the forecast period.
Recent technological advancements have created numerous opportunities for the expansion of the direct-to-consumer genetic testing market. The development of tailored testing kits for specific therapeutic areas and the rising incidence of chronic diseases are particularly beneficial for the market in Germany.
Key Players in the Direct-to-Consumer Genetic Testing Market
The analysis of the direct-to-consumer genetic testing market includes several key players, such as Genesis Healthcare Co, Ancestry Genomics Inc, Color Health Inc, Helix Inc, Myriad Genetics, Inc, Living DNA Ltd, 23andMe Inc, Genetic Technologies Ltd, Gene By Gene Ltd, and Full Genomes Corp Inc.
Key primary and secondary sources utilized in the preparation of this report on the direct-to-consumer genetic testing market include the World Health Organization (WHO), the FDA (Food and Drug Administration), the UK Genetic Testing Network, the French National Authority for Health, and the National Institutes of Health.